683 related articles for article (PubMed ID: 22394547)
21. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
22. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
23. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.
Truong L; Allbutt H; Kassiou M; Henderson JM
Behav Brain Res; 2006 Apr; 169(1):1-9. PubMed ID: 16413939
[TBL] [Abstract][Full Text] [Related]
24. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
25. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
[TBL] [Abstract][Full Text] [Related]
26. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
28. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Cole DG; Growdon JH; DiFiglia M
Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280
[TBL] [Abstract][Full Text] [Related]
29. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
[TBL] [Abstract][Full Text] [Related]
30. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
Ogura T; Ogata M; Akita H; Jitsuki S; Akiba L; Noda K; Hoka S; Saji M
Neurosci Res; 2005 Mar; 51(3):299-308. PubMed ID: 15710494
[TBL] [Abstract][Full Text] [Related]
31. The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.
Bagga V; Dunnett SB; Fricker RA
Behav Brain Res; 2015 Jul; 288():107-17. PubMed ID: 25841616
[TBL] [Abstract][Full Text] [Related]
32. Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism.
Adu TS; Mabandla MV
Metab Brain Dis; 2019 Dec; 34(6):1557-1564. PubMed ID: 31332728
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
35. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
36. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
Moore AE; Cicchetti F; Hennen J; Isacson O
Exp Neurol; 2001 Dec; 172(2):363-76. PubMed ID: 11716560
[TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
[TBL] [Abstract][Full Text] [Related]
38. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
Peneder TM; Scholze P; Berger ML; Reither H; Heinze G; Bertl J; Bauer J; Richfield EK; Hornykiewicz O; Pifl C
Neuroscience; 2011 Apr; 180():280-92. PubMed ID: 21333719
[TBL] [Abstract][Full Text] [Related]
39. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Iancu R; Mohapel P; Brundin P; Paul G
Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
[TBL] [Abstract][Full Text] [Related]
40. Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease.
Henning J; Strauss U; Wree A; Gimsa J; Rolfs A; Benecke R; Gimsa U
Neurosci Res; 2008 Dec; 62(4):246-53. PubMed ID: 18824050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
